Trial Profile
Prediction of ARrhythmic Events With Positron Emission Tomography II
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Flubrobenguane-(18F) (Primary)
- Indications Heart arrest; Heart failure; Ischaemic heart disorders; Myocardial infarction
- Focus Diagnostic use
- Acronyms PAREPET II
- 31 Jan 2024 Planned End Date changed from 2 May 2024 to 31 Dec 2025.
- 31 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2025.
- 31 Jan 2024 Status changed from recruiting to active, no longer recruiting.